Morgan Stanley Maintains Equal-Weight on Ascendis Pharma, Raises Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $116 to $140.
May 16, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on Ascendis Pharma and increased the price target from $116 to $140, indicating a positive outlook.
The increase in the price target from $116 to $140 by a reputable analyst at Morgan Stanley suggests a positive outlook for Ascendis Pharma. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100